(Albany, United States) As per DelveInsight’s assessment, globally, the Plaque Psoriasis pipeline constitutes 75+ key companies continuously working towards developing 75+ Plaque Psoriasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Plaque Psoriasis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Plaque Psoriasis NDA approvals (if any), and product development activities comprising the technology, Plaque Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Plaque Psoriasis pipeline treatment landscape of the report, click here @ Plaque Psoriasis Pipeline Outlook

 

Key Takeaways from the Plaque Psoriasis Pipeline Report

• DelveInsight’s Plaque Psoriasis Pipeline analysis depicts a robust space with 75+ active players working to develop 75+ pipeline treatment therapies.
• The leading Plaque Psoriasis Companies working in the market include Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, and others
• Promising Plaque Psoriasis Pipeline Therapies in the various stages of development include Tapinarof, Bimekizumab, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), DUR-928 Topical Solution, alefacept, IDP-118 Lotion, Etanercept, CHS-0214, mometasone furoate, nortriptyline HCl, and others.
• On May 2023, Samsung Bioepis Co., Ltd announced a study of phase 4 clinical trials for Humira (Adalimumab) and SB5 (Adalimumab Biosimilar). This is a Phase IV, randomized, double-blind, parallel-group, multiple-dose, active comparator, multicenter clinical study to evaluate the pharmacokinetics, efficacy, safety, and immunogenicity of SB5 versus Humira in subjects with moderate to severe chronic plaque psoriasis.
• On June 2023, Affibody announced a study of phase 2 clinical trials for ABY-035. This randomized, double-blinded dose-finding study evaluates four dose levels of ABY-035, in comparison to placebo, in subjects with moderate to severe plaque psoriasis. The study consists of 52-week Core study and two optional 52-week periods, Extension and Prolongation of Extension.

 

Plaque Psoriasis Overview

Psoriasis is recognized as the most prevalent immune-mediated inflammatory disease, involving skin and joints and associated with abnormalities of other systems. Plaque psoriasis is the commonest clinical type of psoriasis.

 

To explore more information on the latest breakthroughs in the Plaque Psoriasis Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight

 

Plaque Psoriasis Emerging Drugs Profile

• ARQ-151: Arcutis Biotherapeutics
• ABY-035: Affibody
• AK101: Akeso Biopharma

 

Plaque Psoriasis Pipeline Therapeutics Assessment

There are approx. 75+ key companies which are developing the therapies for Plaque Psoriasis. The Plaque Psoriasis companies which have their Plaque Psoriasis drug candidates in the most advanced stage, i.e. preregistration include, Arcutis Biotherapeutics.

 

Request a sample and discover the recent advances in Plaque Psoriasis Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight

 

Plaque Psoriasis Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Plaque Psoriasis Therapeutics Market include-

Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, and others.

 

Dive deep into rich insights for drugs for Plaque Psoriasis Pipeline, click here for Plaque Psoriasis Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight

 

Scope of the Plaque Psoriasis Pipeline Report

• Coverage- Global
• Plaque Psoriasis Companies- Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, and others.
• Plaque Psoriasis Pipeline Therapies- Tapinarof, Bimekizumab, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), DUR-928 Topical Solution, alefacept, IDP-118 Lotion, Etanercept, CHS-0214, mometasone furoate, nortriptyline HCl, and others.
• Plaque Psoriasis Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Plaque Psoriasis Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Plaque Psoriasis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Plaque Psoriasis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. ARQ-151: Arcutis Biotherapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ABY-035: Affibody
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CT303: GC Cell
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Plaque Psoriasis Key Companies
21. Plaque Psoriasis Key Products
22. Plaque Psoriasis- Unmet Needs
23. Plaque Psoriasis- Market Drivers and Barriers
24. Plaque Psoriasis- Future Perspectives and Conclusion
25. Plaque Psoriasis Analyst Views
26. Plaque Psoriasis Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services